[{"address1": "822 A1A North", "address2": "Suite 306", "city": "Ponte Vedra", "state": "FL", "zip": "32082", "country": "United States", "phone": "904 300 0701", "website": "https://www.cadrenal.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome. Cadrenal Therapeutics, Inc. was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.", "fullTimeEmployees": 4, "companyOfficers": [{"maxAge": 1, "name": "Mr. Quang X. Pham", "age": 58, "title": "Chairman & CEO", "yearBorn": 1965, "fiscalYear": 2023, "totalPay": 967000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Matthew K. Szot CPA, CPA", "age": 49, "title": "Co-Founder & CFO", "yearBorn": 1974, "fiscalYear": 2023, "totalPay": 594890, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Douglas W. Losordo FACC, FAHA, M.D.", "age": 65, "title": "Chief Medical Officer", "yearBorn": 1958, "fiscalYear": 2023, "totalPay": 528690, "exercisedValue": 0, "unexercisedValue": 12487}, {"maxAge": 1, "name": "Mr. Jeffrey  Cole", "title": "Chief Operating Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 11.23, "open": 11.27, "dayLow": 11.27, "dayHigh": 14.39, "regularMarketPreviousClose": 11.23, "regularMarketOpen": 11.27, "regularMarketDayLow": 11.27, "regularMarketDayHigh": 14.39, "forwardPE": -2.8601696, "volume": 71290, "regularMarketVolume": 71290, "averageVolume": 34208, "averageVolume10days": 41380, "averageDailyVolume10Day": 41380, "marketCap": 15959970, "fiftyTwoWeekLow": 5.4, "fiftyTwoWeekHigh": 32.55, "fiftyDayAverage": 9.36086, "twoHundredDayAverage": 9.317615, "currency": "USD", "enterpriseValue": 9379254, "floatShares": 502250, "sharesOutstanding": 1182220, "sharesShort": 18033, "sharesShortPriorMonth": 15819, "sharesShortPreviousMonthDate": 1724976000, "dateShortInterest": 1727654400, "sharesPercentSharesOut": 0.0153, "heldPercentInsiders": 0.52939, "heldPercentInstitutions": 0.021930002, "shortRatio": 0.43, "shortPercentOfFloat": 0.0254, "impliedSharesOutstanding": 1182220, "bookValue": 3.741, "priceToBook": 3.608661, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1719705600, "netIncomeToCommon": -6236781, "trailingEps": -4.8, "forwardEps": -4.72, "lastSplitFactor": "1:15", "lastSplitDate": 1724112000, "enterpriseToEbitda": -1.415, "52WeekChange": 0.44927537, "SandP52WeekChange": 0.329566, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "CVKD", "underlyingSymbol": "CVKD", "shortName": "Cadrenal Therapeutics, Inc.", "longName": "Cadrenal Therapeutics, Inc.", "firstTradeDateEpochUtc": 1674225000, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "ba078ec3-1bff-3797-99d9-a2e1a25e88f8", "messageBoardId": "finmb_1793167154", "gmtOffSetMilliseconds": -14400000, "currentPrice": 13.5, "targetHighPrice": 60.0, "targetLowPrice": 30.0, "targetMeanPrice": 45.0, "targetMedianPrice": 45.0, "recommendationMean": 2.0, "recommendationKey": "buy", "numberOfAnalystOpinions": 3, "totalCash": 5037174, "totalCashPerShare": 4.72, "ebitda": -6626399, "totalDebt": 8796, "quickRatio": 3.439, "currentRatio": 3.716, "debtToEquity": 0.22, "returnOnAssets": -0.91899, "returnOnEquity": -1.74013, "freeCashflow": -2539742, "operatingCashflow": -4687845, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-10-14"}]